Mater Clinical Trials
Mater conducts clinical trials in a range of therapeutic areas including Cancer, Neurology, Medicine, Orthopaedics Surgery and Acute Care, and Mothers’ and Babies Health. Clinical trials are an essential component of healthcare. They provide the evidence to evaluate the safety and efficacy of new treatments and diagnostics, and provide alternative treatment options for patients with unmet needs.
Mater currently has over 200 active clinical trials. These trials include commercial pharmaceutical and medical device studies, as well as collaborative group studies and investigator-initiated studies, led by Mater’s researchers and collaborators at The University of Queensland and other leading Australian and international medical research institutions.
Without volunteers, clinical trials are not possible. If you are interested in being involved – you may be a patient with a new diagnosis, a patient with a long term diagnosis or a healthy volunteer – view available trials below or contact the Mater Clinical Trials team.
A clinical trial to investigate the efficacy, safety and tolerability of ML-004 for treatment of the core behavioural symptoms in Autistic people
A placebo controlled clinical trial to evaluate direct administration of anti-epileptic medication to the brain in patients with treatment refractory focal epilepsy
Neuromodulation Using Scanning Ultrasound in Alzheimer’s Disease
A clinical trial to test the effectiveness and safety of CVL-865 for treatment of drug-resistant focal onset epilepsy
Evaluating eptinezumab with a brief educational intervention for prevention of migraine in patients with migraine and medication overuse headache
A clinical trial to assess the safety of an experimental device implanted under the scalp for continuous recording of brain electrical activity associated the epileptic seizures
This study is trialing a novel anti-epileptic medication called XEN1101 in patients who suffer from primary generalized tonic-clonic seizures and have not achieved satisfactory seizure control using standard therapies.
This study is trialing a novel anti-epileptic medication called XEN1101 in focal epilepsy patients who have not achieved satisfactory seizure control on at least two anti-epileptic medications.